Definition, product boundary, and intended use
Sleep therapy software is a software function intended to improve a defined sleep disorder, a treatment-related behavior, or a patient function by repeatedly delivering an intervention with a describable mechanism and dose. It may operate independently or within a phone, website, bedside terminal, connected treatment device, or clinical system. The nature of the product follows from its intended use, outputs, degree of automation, and consequences of failure—not from labels such as app, platform, artificial intelligence, or digital therapeutic.
Therapy software differs from a sleep diary, snoring recorder, alarm, white-noise player, educational course, appointment service, generic wellness advice, or dashboard that only displays data to professionals. Monitoring and education may be treatment components, but a function should be evaluated as therapy only when it converts inputs into predefined therapeutic activity, specifies the population and contraindications, and supports its clinical claims with proportionate evidence. Availability in an application store, registration, or a technical certificate in one jurisdiction does not establish every promoted use.
Product information should separately state the indication, age group, disease stage, diagnostic prerequisite, therapeutic goal, users, use environment, human support, expected course, and exit criteria. Within one program, a sleep-aid claim, insomnia treatment, circadian adjustment, nightmare intervention, and respiratory-treatment support are different functions. A broad promise to improve sleep must not obscure their different evidence and risks.
Indication architecture and module isolation
A chronic insomnia module may deliver multicomponent cognitive behavioral therapy, including education about sleep regulation, stimulus control, a sleep window, and cognitive strategies; sleep hygiene alone is not equivalent to complete CBT-I. An obstructive sleep apnea module usually supports education, troubleshooting, and follow-up for an established treatment rather than diagnosing disease from consumer sensor data or changing PAP pressure autonomously. A circadian module may involve timed light, darkness, scheduling, or another professionally assessed measure. Its effect and risk depend heavily on phase and timing, so a uniform plan cannot be generated from a wish to sleep earlier.
A nightmare or trauma-related module should distinguish generic relaxation, imagery rehearsal, and trauma-focused treatment. A chatbot must not coerce trauma disclosure or independently conduct high-risk exposure. Children, pregnancy and the postpartum period, older adults, bipolar disorder, epilepsy, serious respiratory disease, and neuromuscular disease require population-specific evidence, supervision, and escalation. Results from a low-risk adult sample cannot simply be transferred to these contexts.
Indications, data, rules, alerts, and evidence should remain isolated across modules. A shared account, interface, content engine, or sensor does not create shared efficacy. When a person has insomnia, OSA, circadian misalignment, and psychological symptoms at the same time, the software should prompt integrated assessment instead of allowing the highest questionnaire score to select one diagnosis and treatment automatically. An untested combination of validated modules can itself change dose, burden, and risk and should be evaluated as a new regimen.
Therapeutic state machine, personalization, and dose integrity
The therapeutic course should be represented as a traceable state machine: eligibility and exclusion, baseline assessment, plan generation, task delivery, completion confirmation, response assessment, pause, escalation, review, and termination. Each state needs required inputs, permitted outputs, failure states, and an accountable role. Personalization is not unlimited content generation. It is the selection of a module, sequence, frequency, or support intensity within a validated range on the basis of reliable information, with disclosure of whether a rule, model, or professional made each material change.
Therapeutic dose includes not only lesson or exercise content but also timing, frequency, duration, feedback, human contact, and quality of completion. Disabled notifications, an incorrect phone clock, time-zone travel, shift work, offline use, a shared device, a missing diary, or sensor disconnection can alter the dose actually delivered. The system should display the plan's time zone and next step and distinguish not delivered, unopened, viewed, completed, and unable to complete. A tap is not proof that therapy occurred, and inferred data must not fill a critical input without disclosure.
Adaptive rules require upper and lower bounds, pause conditions, outlier handling, and a reversible path. If a generative model explains content or conducts a conversation, it should be constrained by approved knowledge, prohibited topics, source traceability, output monitoring, and human takeover. Fluent language does not confer authority to prescribe. A change to a sleep window, light timing, trauma exercise, treatment-device setting, or clinical escalation needs stricter validation than an ordinary interface-copy change.
Risk screening, abnormal response, and human accountability
Before activation and during treatment, the service should screen for conditions that may change suitability. These include safety-critical daytime sleepiness, possible sleep apnea or hypoventilation, abnormal nocturnal behavior, mania or psychotic symptoms, risk of harm to self or others, epilepsy, unstable substance use, pregnancy, major medication changes, and caregiving or work constraints that conflict with behavioral treatment. A positive screen is not an automatic diagnosis, but it should trigger a defined pause, modification, or transfer to a qualified person.
Sleep restriction or a schedule shift may temporarily increase sleepiness; timed light may be unsuitable in some ocular, medication, or mood contexts; trauma content may cause intense distress; an adherence module may conceal a residual respiratory problem. Risk information should follow the mechanism rather than rely on one disclaimer for every module. The software must not independently advise stopping or changing prescribed medication, provide individualized supplement doses, adjust PAP or oxygen settings, or treat temporary symptom improvement as proof that the original diagnosis has resolved.
Crisis design must distinguish immediate from asynchronous service. Chest pain, severe breathing difficulty, altered consciousness, acute neurologic symptoms, or imminent risk of harm belongs in local emergency care rather than an application queue. An ordinary clinical alert also needs a severity, accountable recipient, response interval, acknowledgement, backup channel after nonresponse, and audit record. A service without continuous staffing must not claim real-time monitoring or guaranteed safety.
Data provenance, interoperability, and explainable records
Inputs may come from a sleep diary, questionnaire, wearable, phone, bedside sensor, PAP device, electronic health record, caregiver, or clinician. Each field should retain its source, time, time zone, unit, device and algorithm version, validity, reason for missingness, and whether it was manually corrected. Sleep stages, respiratory events, and recovery scores produced by consumer devices are not clinical ground truth. The interface and decision rules must preserve the distinction among measurement, inference, patient report, and medical judgment.
Interoperability means more than a successful connection. Mapping tests should cover identity matching, duplicate or out-of-order messages, unit conversion, daylight-saving and time-zone changes, offline backfill, device replacement, withdrawal of authorization, and partial-field loss. The snapshot used to make a treatment plan should remain distinguishable from later backfilled data so that history cannot silently rewrite a decision already executed. When an external interface changes a field definition or ends service, the product needs a safe degraded mode rather than continued output of a falsely precise plan.
Patients and professionals should be able to inspect the plan basis, material inputs, recent changes, unresolved alerts, and human responsibility. An explanation should not expose unrelated sensitive information or reduce a complex model to a false single cause. Incorrect inputs, algorithmic conclusions, and treatment tasks should be correctable and revocable with version history. An exported summary should state uncertainty and the time for which it applies so that a later organization does not treat it as a permanent diagnosis.
Clinical evidence, version validation, and procurement
Clinical evaluation should first establish a valid association between the therapeutic mechanism and target condition, then show that the software correctly implements its inputs, rules, and outputs, and finally demonstrate meaningful clinical results with the released version in the intended population. A study should report diagnostic methods, eligibility, comparator services, human support, actual exposure, attrition, adverse events, and follow-up. A wait-list comparison, engagement alone, or a statistically significant sleep score does not adequately support a broad treatment claim.
Outcomes should follow the indication. An insomnia claim may assess severity, function, and remission; OSA support should separate treatment use, symptoms, and effectiveness; circadian treatment should validate phase-related and real-world schedule outcomes; nightmare treatment should report nightmares, sleep, trauma symptoms, and safety. An average effect for one module does not establish another module, and a short-term surrogate cannot prove fewer accidents, cardiovascular events, or long-term relapses. Subgroup performance, digital access, human workload, and outcomes among people who leave are also part of value.
Procurement and deployment should identify the product version, content package, model, sensors, interfaces, and service configuration. Every change should be assessed for effects on population, mechanism, dose, output interpretation, and risk controls. An adaptive model also needs predefined permitted changes, validation methods, and monitoring boundaries. Real-world surveillance cannot replace predeployment evidence, but it should detect drift, complaints, bias, unexpected use, and new hazards and support rollback, suspension, or revalidation.
Human factors, privacy, cybersecurity, and exit
Usability directly determines whether therapy is performed correctly. Testing should include target patients with low vision, color-vision differences, hearing or dexterity limitations, cognitive burden, limited health literacy, different languages, and assistive technologies—not only healthy employees completing an ideal path. Critical risk information must not depend only on color, a transient notification, or a complex gesture. Context should be recoverable after interruption, and errors should be discoverable and reversible. Accessibility conformance is a starting point; real-patient misoperation, help seeking, abandonment, and comprehension still need observation.
Sleep data can reveal a diagnosis, mental state, household schedule, bed partner, location, work shift, and treatment device. The product should minimize collection, separate purposes, enforce role-based access and multifactor authentication, encrypt data in transit and at rest, maintain reviewable logs, and define retention and secure deletion. Diagnosis, questionnaires, diaries, and device identifiers should not flow to advertising or unrelated tracking services. Users should be able to inspect authorization, export information, correct records, and withdraw nonessential sharing.
Phones, cloud services, third-party content, sensors, and clinical systems create a dependency chain. Suppliers should maintain a component inventory, vulnerability handling, signed updates, backup recovery, incident communication, and outage exercises. Even during network failure or vendor exit, a patient needs instructions for safely pausing or continuing established care, reaching the responsible team, and obtaining records. Service closure must not abruptly lock treatment data or sever necessary support; contracts should define notice, migration format, transfer of accountability, and an alternative pathway in advance.